![]() |
|
|
Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, MA 02118
3To whom correspondence should be addressed. E-mail: jloscalz{at}bu.edu.
L-arginine, the principal substrate for endothelial nitric oxide synthase, is oxidized to L-citrulline and nitric oxide. Endothelial dysfunction is associated with decreased bioactive nitric oxide production, an abnormality observed in atherothrombosis. Acute or chronic administration of supplemental L-arginine enhances endothelial nitric oxide production and improves endothelial function in the setting of atherothrombosis. The mechanisms by which L-arginine improves endothelial nitric oxide bioactivity include increased intracellular uptake via the high-affinity cationic transporter; substrate competition with asymmetric dimethylarginine, a naturally occurring inhibitor of nitric oxide synthase; direct antioxidant activity; stimulated release of histamine from mast cells, which produces a vasodilator response; decreased activity of norepinephrine, which promotes the effect of endogenous vasodilators including nitric oxide; and increased insulin secretion, which causes vasodilation. By virtue of its link to methyl group metabolism, supplemental L-arginine can, however, also increase the production of S-adenosylhomocysteine from S-adenosylmethionine through the methylation-dependent generation of creatine from guanidinoacetate. This reaction can theoretically lead to increased homocysteine synthesis from its S-adenosyl derivative, which itself can have adverse effects on endothelial function. The interrelationships among these effects of L-arginine are reviewed here, and the potential benefits and risks of L-arginine supplementation are discussed.
KEY WORDS: arginine atherothrombosis vasodilation nitric oxide
This article has been cited by other articles:
![]() |
G. S. Getz and C. A. Reardon Nutrition and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2499 - 2506. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mariotti, J. F. Huneau, I. Szezepanski, K. J. Petzke, Y. Aggoun, D. Tome, and D. Bonnet Meal Amino Acids with Varied Levels of Arginine do Not Affect Postprandial Vascular Endothelial Function in Healthy Young Men J. Nutr., June 1, 2007; 137(6): 1383 - 1389. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Grimble Adverse Gastrointestinal Effects of Arginine and Related Amino Acids J. Nutr., June 1, 2007; 137(6): 1693S - 1701S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lucotti, E. Setola, L. D. Monti, E. Galluccio, S. Costa, E. P. Sandoli, I. Fermo, G. Rabaiotti, R. Gatti, and P. Piatti Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E906 - E912. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Morris JR Arginine metabolism in vascular biology and disease Vascular Medicine, July 1, 2005; 10(1_suppl): S83 - S87. [Abstract] [PDF] |
||||
![]() |
S. M Morris Jr Arginine metabolism in vascular biology and disease Vascular Medicine, May 1, 2005; 10(2_suppl): S83 - S87. [Abstract] [PDF] |
||||
![]() |
C. Baylis Session III: Arginine and Pathophysiology I--Discussion Summary J. Nutr., October 1, 2004; 134(10): 2818S - 2819S. [Full Text] [PDF] |
||||